{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:14:26Z","timestamp":1791465266237,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psoriasis is an autoimmune inflammatory skin disease that affects 0.5\u20133% of the world\u2019s population and current treatment options are posed with limitations. The reduced risk of failure in clinical trials for repositioned drug candidates and the time and cost-effectiveness has popularized drug reposition and computational methods in the drug research community.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The current study attempts to reposition approved drugs for the treatment of psoriasis by docking about 2000 approved drug molecules against fifteen selected and validated anti-psoriatic targets. The docking results showed that a good number of the dataset interacted favorably with the targets as most of them had \u2212\u200911.00 to \u2212\u200910.00\u2009kcal\/mol binding free energies across the targets. The percentage of the dataset with binding affinity higher than the co-crystallized ligands ranged from 34.76% (JAK-3) to 0.73% (Rac-1). It was observed that 12 out of the 0.73% outperformed all the co-crystallized ligands across the 15 studied proteins. All the 12 drugs identified are currently indicated as either antiviral or anticancer drugs and are of purine and pyrimidine nuclei. This is not surprising given that there is similarity in the mechanism of the mentioned diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study, therefore, suggests that; antiviral and anticancer drugs could have anti-psoriatic effects, and molecules with purine and pyrimidine structural architecture are likely templates to consider in developing anti-psoriatic agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-021-03359-2","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T14:03:14Z","timestamp":1625493794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A computational multi-targeting approach for drug repositioning for psoriasis treatment"],"prefix":"10.1186","volume":"21","author":[{"given":"Akachukwu","family":"Ibezim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Onah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebubechukwu N.","family":"Dim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidele","family":"Ntie-Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"3359_CR1","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization (2016). Global report on psoriasis. (https:\/\/apps.who.int\/iris\/handle\/10665\/204417). ISBN: 978924 1565189. Accessed 5 Nov 2019."},{"issue":"4","key":"3359_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","volume":"34","author":"MA Lowes","year":"2013","unstructured":"Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174\u201381. https:\/\/doi.org\/10.1016\/j.it.2012.11.005.","journal-title":"Trends Immunol"},{"issue":"2","key":"3359_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investigative Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Investigative Dermatol"},{"key":"3359_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12079-015-0297-3","volume":"9","author":"J Sharma","year":"1999","unstructured":"Sharma J, Balakrishnan L, Datta KK. A knowledgebase resource for interleukin-17 family mediated signaling. J Cell Comm Signaling. 1999;9:291\u20136. https:\/\/doi.org\/10.1007\/s12079-015-0297-3.","journal-title":"J Cell Comm Signaling"},{"issue":"19","key":"3359_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2319-7250.195569","volume":"18","author":"A Ghosh","year":"2017","unstructured":"Ghosh A, Panda S. Recent understanding of the etiopathogenesis of psoriasis. Indian J Pediatric Dermatol. 2017;18(19):1\u20138. https:\/\/doi.org\/10.4103\/2319-7250.195569.","journal-title":"Indian J Pediatric Dermatol"},{"issue":"19","key":"3359_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3949\/ccjm.79a.11133","volume":"79","author":"WD Villasenor-ParkJ","year":"2012","unstructured":"Villasenor-ParkJ WD, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Clevel and Clinic J Med. 2012;79(19):413\u201323. https:\/\/doi.org\/10.3949\/ccjm.79a.11133.","journal-title":"Clevel and Clinic J Med"},{"key":"3359_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CCID.S67534","volume":"7","author":"AS Lonnberg","year":"2014","unstructured":"Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmetic Investig Dermatol. 2014;7:251\u20139. https:\/\/doi.org\/10.2147\/CCID.S67534.","journal-title":"Clin Cosmetic Investig Dermatol"},{"issue":"19","key":"3359_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","volume":"23","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opinion Immunol. 2011;23(19):613\u20139. https:\/\/doi.org\/10.1016\/j.coi.2011.07.006.","journal-title":"Curr Opinion Immunol"},{"issue":"4","key":"3359_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341. https:\/\/doi.org\/10.1007\/s40265-014-0191-y.","journal-title":"Drugs"},{"issue":"19","key":"3359_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ddr.21263","volume":"76","author":"T Torres","year":"2015","unstructured":"Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(19):215\u201327. https:\/\/doi.org\/10.1002\/ddr.21263.","journal-title":"Drug Dev Res"},{"issue":"19","key":"3359_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(19):673\u201383. https:\/\/doi.org\/10.1038\/nrd1468.","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"3359_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.2013.1","volume":"93","author":"MR Hurle","year":"2013","unstructured":"Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Therapeut. 2013;93(19):335\u201341. https:\/\/doi.org\/10.1038\/clpt.2013.1.","journal-title":"Clin Pharmacol Therapeut"},{"issue":"19","key":"3359_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-018-0050-7","volume":"4","author":"RG Govindaraj","year":"2018","unstructured":"Govindaraj RG, Naderi M, Singha M, Lemoine J, Brylinski M. Large-scale computational drug repositioning to find treatments for rare diseases. Syst Biol Appl. 2018;4(19):1\u201310. https:\/\/doi.org\/10.1038\/s41540-018-0050-7.","journal-title":"Syst Biol Appl"},{"issue":"4","key":"3359_CR14","doi-asserted-by":"publisher","first-page":"e1004852","DOI":"10.1371\/journal.pcbi.1004852","volume":"12","author":"RA Rodriguez-Esteban","year":"2016","unstructured":"Rodriguez-Esteban RA. Drug-centric view of drug development: how drugs spread from disease to disease. PLoS Comput Biol. 2016;12(4):e1004852. https:\/\/doi.org\/10.1371\/journal.pcbi.1004852.","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"3359_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/gm326","volume":"4","author":"YY Li","year":"2012","unstructured":"Li YY, Jones JMS. Drug repositioning for personalized medicine. Genome Med. 2012;4(3):27. https:\/\/doi.org\/10.1186\/gm326.","journal-title":"Genome Med"},{"issue":"19","key":"3359_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as Cancer therapeutics. Front Oncol. 2017;7(19):273\u20133607. https:\/\/doi.org\/10.3389\/fonc.2017.00273.","journal-title":"Front Oncol"},{"issue":"19","key":"3359_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"L Sleire","year":"2017","unstructured":"Sleire L, F\u00f8rde HE, Netland IA, Leiss L, Skeie BS, Enger P\u00d8. Drug repurposing in cancer. Pharmacol Res. 2017;124(19):74\u201391. https:\/\/doi.org\/10.1016\/j.phrs.2017.07.013.","journal-title":"Pharmacol Res"},{"key":"3359_CR18","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1021\/ci5003697","volume":"54","author":"F Ntie-Kang","year":"2014","unstructured":"Ntie-Kang F, Nwodo NJ, Ibezim A, Simoben CV, Karaman B, Ngwa VF, et al. Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model. 2014;54:2433\u201350. https:\/\/doi.org\/10.1021\/ci5003697.","journal-title":"J Chem Inf Model"},{"issue":"1","key":"3359_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00044-016-1739-z","volume":"26","author":"A Ibezim","year":"2016","unstructured":"Ibezim A, Nwodo NJ, Nnaji NJN, Ujam OT, Olubiyi OO, Mbah CJ. In silico investigation of morpholines as novel class of trypanosomal triosephosphate isomerase inhibitors. Med Chem Res. 2016;26(1):180\u20139. https:\/\/doi.org\/10.1007\/s00044-016-1739-z.","journal-title":"Med Chem Res"},{"key":"3359_CR20","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/slct.201702972","volume":"3","author":"A Ibezim","year":"2018","unstructured":"Ibezim A, Obi BC, Oforkansi MN, Mbah CJ, Nwodo NJ. Discovery of trypanocidal bioactive leads by docking study, molecular dynamic simulation and in vivo screening. ChemistrySelect. 2018;3:2386\u20139. https:\/\/doi.org\/10.1002\/slct.201702972.","journal-title":"ChemistrySelect"},{"issue":"2","key":"3359_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1573409913666170119114859","volume":"13","author":"A Ibezim","year":"2017","unstructured":"Ibezim A, Olubiyi OO, Ata K, Mbah CJ, Nwodo NJ. Structure-based study of natural poducts with anti-Schistosoma activity. Curr Comput Aided Drug Des. 2017;13(2):91\u2013100. https:\/\/doi.org\/10.2174\/1573409913666170119114859.","journal-title":"Curr Comput Aided Drug Des"},{"key":"3359_CR22","doi-asserted-by":"publisher","first-page":"14416","DOI":"10.1002\/slct.202003784","volume":"5","author":"A Ibezim","year":"2020","unstructured":"Ibezim A, Onoabedje EA, Adaka IC, Omeje KO, Onoabedje US, Obi BC. Carboxamides bearing sulfonamide functionality as potential novel phospholipase A2 inhibitors. ChemistrySelect. 2020;5:14416\u201321. https:\/\/doi.org\/10.1002\/slct.202003784.","journal-title":"ChemistrySelect"},{"key":"3359_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7324\/JAPS.2015.50622","volume":"5","author":"A Ibezim","year":"2015","unstructured":"Ibezim A, Onyia K, Ntie-Kang F, Nwodo NJ. Drug-like properties of potential anti-cancer compounds from Cameroonian flora: a virtual study. J Applied Pharm Sci. 2015;5:133\u20137. https:\/\/doi.org\/10.7324\/JAPS.2015.50622.","journal-title":"J Applied Pharm Sci"},{"issue":"19","key":"3359_CR24","doi-asserted-by":"publisher","first-page":"e00229","DOI":"10.1016\/j.sciaf.2019.e00229","volume":"7","author":"FC Asogwa","year":"2020","unstructured":"Asogwa FC, Ibezim A, Ntie-Kang F, Asogwa CJ, Okoye COB. Anti-psoriatic and immunomodulatory evaluation of Psorospermum febrifugum Spach and its phytochemicals. Sci Afr. 2020;7(19):e00229. https:\/\/doi.org\/10.1016\/j.sciaf.2019.e00229.","journal-title":"Sci Afr"},{"issue":"12","key":"3359_CR25","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","volume":"60","author":"JJ Irwin","year":"2020","unstructured":"Irwin JJ, Tang KG, Young J, Dandarchuluun C, Wong BR, Khurelbaatar M, et al. ZINC20-a free Ultralarge-scale chemical database for ligand discovery. J Chem Inf Model. 2020;60(12):6065\u201373. https:\/\/doi.org\/10.1021\/acs.jcim.0c00675.","journal-title":"J Chem Inf Model"},{"key":"3359_CR26","unstructured":"Molecular Operating Environment (MOE), 2014.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2014."},{"issue":"5-6","key":"3359_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","volume":"17","author":"TA Halgren","year":"1996","unstructured":"Halgren TA. Merck molecular forcefield. J Comput Chem. 1996;17(5-6):490\u2013641. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P.","journal-title":"J Comput Chem"},{"issue":"19","key":"3359_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28(19):235\u2013342. https:\/\/doi.org\/10.1093\/nar\/28.1.235.","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"3359_CR29","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1021\/jp984217f","volume":"103","author":"WRP Scott","year":"1999","unstructured":"Scott WRP, Hunenberger PH, Tironi IG, Mark AE, Billeter SR, Fennen J, et al. The GROMOS biomolecular simulation program package. J Phys Chem. 1999;103(19):3596\u2013607. https:\/\/doi.org\/10.1021\/jp984217f.","journal-title":"J Phys Chem"},{"issue":"19","key":"3359_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7861\/clinmedicine.14-1-47","volume":"14","author":"A Aslam","year":"2014","unstructured":"Aslam A, Griffiths CEM. Drug therapies in dermatology. Clinic Med. 2014;14(19):47\u201353. https:\/\/doi.org\/10.7861\/clinmedicine.14-1-47.","journal-title":"Clinic Med"},{"issue":"19","key":"3359_CR31","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1172\/JCI85738","volume":"126","author":"MCG Winge","year":"2016","unstructured":"Winge MCG, Ohyama B, Dey CN, Boxer LM, Li W, et al. () RAC1 activation drives pathologic interactions between the epidermis and immune cells. J Clin Invest. 2016;126(19):2661\u201377. https:\/\/doi.org\/10.1172\/JCI85738.","journal-title":"J Clin Invest"},{"issue":"19","key":"3359_CR32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"K Ronholt","year":"2017","unstructured":"Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(19):2297\u20133607. https:\/\/doi.org\/10.3390\/ijms18112297.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3359_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","volume":"60","author":"A Thorarensen","year":"2017","unstructured":"Thorarensen A, Dowty ME, Banker ME, et al. Design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo [2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF06651600) allowing for the interrogation of JAK3 signaling in humans. J Med Chem. 2017;60(19):1971\u201393. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01694.","journal-title":"J Med Chem"},{"issue":"4","key":"3359_CR34","doi-asserted-by":"publisher","first-page":"082","DOI":"10.7324\/JAPS.2019.90410","volume":"9","author":"A Ibezim","year":"2019","unstructured":"Ibezim A, Ezechukwu EA. In-silico study of flavonoids from Cassia tora as potential anti-psoriatic agent. J Appl Pharmaceut Sci. 2019;9(4):082\u20137. https:\/\/doi.org\/10.7324\/JAPS.2019.90410.","journal-title":"J Appl Pharmaceut Sci"},{"key":"3359_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/0976-500X.142464","volume":"5","author":"KH Bhatia","year":"1999","unstructured":"Bhatia KH, Singh H, Grewal N, Natt KN. () Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacotherap. 1999;5:278\u201384. https:\/\/doi.org\/10.4103\/0976-500X.142464.","journal-title":"J Pharmacol Pharmacotherap"},{"issue":"19","key":"3359_CR36","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"JD Daniel","year":"2007","unstructured":"Daniel JD, Daohai Y, Jeffrey LJ, Steven EC, Richard MS, Alison TS, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-linkage acute lymphoblastic leukaemia or lymphoblastic lymphoma: Cancer and leukemia group B study 19801. Blood. 2007;109(19):5136\u201342. https:\/\/doi.org\/10.1182\/blood-2006-11-056754.","journal-title":"Blood"},{"key":"3359_CR37","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.3748\/wjg.v20.i20.6262","volume":"20","author":"T Ceen-Ming","year":"1999","unstructured":"Ceen-Ming T, Tung OU, Yun Y. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol. 1999;20:6262\u201378. https:\/\/doi.org\/10.3748\/wjg.v20.i20.6262.","journal-title":"World J Gastroenterol"},{"key":"3359_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/BTT.S10123","volume":"4","author":"A Pession","year":"2010","unstructured":"Pession A, Masetti R, Kleinschmidt K, Martoni A. Use of clofarabine in acute childhood leukaemia. Biol: Targets Therapy. 2010;4:111\u20138. https:\/\/doi.org\/10.2147\/BTT.S10123.","journal-title":"Biol: Targets Therapy"},{"key":"3359_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s40506-014-0021-5","volume":"6","author":"BH Tan","year":"2014","unstructured":"Tan BH. Cytomegalovirus treatment. Curr Treatment Options in Inf Dis. 2014;6:256\u201370. https:\/\/doi.org\/10.1007\/s40506-014-0021-5.","journal-title":"Curr Treatment Options in Inf Dis"},{"issue":"19","key":"3359_CR40","doi-asserted-by":"publisher","first-page":"e0115686","DOI":"10.1371\/journal.pone.0115686","volume":"10","author":"C Focacetti","year":"2015","unstructured":"Focacetti C, Bruno A, Magnani E, Bartolino D, Principi E, et al. Effects of 5-flourouracil on morphology, cell cycle proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015;10(19):e0115686. https:\/\/doi.org\/10.1371\/journal.pone.0115686.","journal-title":"PLoS One"},{"issue":"19","key":"3359_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IDR.S96164","volume":"9","author":"A Sauerbrei","year":"2016","unstructured":"Sauerbrei A. Optimal management of genital herpes: current perspectives. Inf Drug Resist. 2016;9(19):129\u201341. https:\/\/doi.org\/10.2147\/IDR.S96164.","journal-title":"Inf Drug Resist"},{"issue":"19","key":"3359_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-10-134","volume":"10","author":"L Zhang","year":"2013","unstructured":"Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virology J. 2013;10(19):1\u201312. https:\/\/doi.org\/10.1186\/1743-422X-10-134.","journal-title":"Virology J"},{"issue":"19","key":"3359_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, et al. Consensus guidelines for the diagnosis and management of patient of with classic hairy cell leukemia. Blood. 2017;129(19):553\u201360. https:\/\/doi.org\/10.1182\/blood-2016-01-689422.","journal-title":"Blood"},{"issue":"3","key":"3359_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","volume":"28","author":"AK Pau","year":"2014","unstructured":"Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin N Am. 2014;28(3):371\u2013402. https:\/\/doi.org\/10.1016\/j.idc.2014.06.001.","journal-title":"Infect Dis Clin N Am"},{"issue":"19","key":"3359_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5114\/wo.2015.55410","volume":"19","author":"I Hus","year":"2015","unstructured":"Hus I, Rolinski J. Current concepts in diagnosis and treatment of chronic lymphocytic leukaemia. Contemp Oncol (Pozn). 2015;19(19):361\u20137. https:\/\/doi.org\/10.5114\/wo.2015.55410.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"10","key":"3359_CR46","doi-asserted-by":"publisher","first-page":"e110153","DOI":"10.1371\/journal.pone.0110153","volume":"9","author":"W Li","year":"2014","unstructured":"Li W, Gong X, Sun M, Zhao X, Gong B, Wei H, et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One. 2014;9(10):e110153. https:\/\/doi.org\/10.1371\/journal.pone.0110153.","journal-title":"PLoS One"},{"issue":"3","key":"3359_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7897\/2230-8407.09336","volume":"9","author":"C Sowmya","year":"2018","unstructured":"Sowmya C, Lavakumar V, Venkateshan N, Anitha P, Senthilnathan B. Current trends in treatment and management of psoriasis: an updated review. Int Res J Pharm. 2018;9(3):6\u201316. https:\/\/doi.org\/10.7897\/2230-8407.09336.","journal-title":"Int Res J Pharm"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-021-03359-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T14:03:27Z","timestamp":1625493807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-021-03359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3359"],"URL":"https:\/\/doi.org\/10.1186\/s12906-021-03359-2","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest among the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}